Tevogen Bio Holdings Inc. (TVGN)
$
1.29
-0.05 (-3.88%)
Key metrics
Financial statements
Free cash flow per share
-0.0814
Market cap
237.2 Million
Price to sales ratio
598.1616
Debt to equity
-0.2360
Current ratio
0.3530
Income quality
0.3714
Average inventory
0
ROE
5.0122
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on the development of off-the-shelf precision T cell therapeutics with applications in virology, oncology, and neurology. The company's lead investigational product, TVGN 489, aims to meet the critical needs of acute-risk COVID-19 patients and addresses specific concerns among individuals suffering from long COVID. The cost of revenue for the company is $0.00 showcasing its production and operational expenses. Furthermore, the net income ratio is 0.00 reflecting the company's profitability margin. In terms of non-core financial activities, the net total of other income and expenses is $39,837,108.00. The company achieved a revenue of $0.00 indicating its niche market focus. The total costs and expenses for the company are -$53,564,488.00 reflecting its overall spending, which is important as it continues to develop innovative therapies that may significantly impact patient care. Based in Warren, New Jersey, Tevogen Bio is committed to advancing its therapeutic offerings in a competitive landscape. In the stock market, Tevogen Bio presents an attractive opportunity as the stock is affordable at $1.34 making it suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 917,684.00 indicating strong liquidity, which may enhance trading activity. With a market capitalization of $237,222,525.00 the company is classified as a small-cap player, positioning it uniquely within the biotechnology sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and addressing urgent health needs. Belonging to the Healthcare sector, Tevogen Bio drives innovation and growth, appealing to those looking for emerging opportunities in the biotechnology field.
Is Tevogen Bio Holdings Inc. (TVGN) a good investment?
Investing in Tevogen Bio Holdings Inc. (TVGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Tevogen Bio Holdings Inc. (TVGN)'s stock forecast?
Analysts predict Tevogen Bio Holdings Inc. stock to fluctuate between $0.26 (low) and $3.09 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Tevogen Bio Holdings Inc.'s market capitalization?
As of 2025-05-30, Tevogen Bio Holdings Inc.'s market cap is $237,222,525, based on 183,893,430 outstanding shares.
How does Tevogen Bio Holdings Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Tevogen Bio Holdings Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Tevogen Bio Holdings Inc. (TVGN) stock?
To buy Tevogen Bio Holdings Inc. (TVGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TVGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Tevogen Bio Holdings Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Tevogen Bio Holdings Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.09 | Growth: 23,300%.
Where can I find Tevogen Bio Holdings Inc.'s investor relations reports?
Visit https://tevogen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Tevogen Bio Holdings Inc.?
You can explore historical data from here
What is the all-time high and low for Tevogen Bio Holdings Inc. stock?
All-time high: $21.09 (2024-02-15) | All-time low: $0.26 (2024-10-09).
What are the key trends affecting Tevogen Bio Holdings Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a planned expansion of TVGN 489's target population to include patients 65 and older. As previously reported in October 2024, the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expansion aims to broaden the market potential of Tevogen's specialty pharmaceuticals. An updated forecast and the risk adjusted net present value (rNPV) will be provided to reflect the inclusion of the 65+ patient population.
globenewswire.com
WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of the Company's upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company's innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization.
globenewswire.com
WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of intent for a facility designed to support Tevogen Bio's cell therapy manufacturing facility.
globenewswire.com
WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. The forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.
globenewswire.com
WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced that the Company will hold its 2025 annual meeting of stockholders (the “Annual Meeting”) via live webcast at 11 a.m. Eastern Time on June 23, 2025. Stockholders of record as of April 30, 2025, will be asked to vote on the re-election of two incumbent director nominees, and the ratification of the Company's independent registered public accounting firm.
globenewswire.com
WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cell therapy production capabilities.
globenewswire.com
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announces its newest effort: Tevogen Generics. This effort is in response to the growing national focus on pharmaceutical affordability and coincides with the recent tariff-related statements from President Donald Trump.
globenewswire.com
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi's leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond.
globenewswire.com
WARREN, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today announced the filing of a new patent with the U.S. Patent and Trademark Office (USPTO) for its under-development T cell vaccine. Unlike many vaccines that primarily induce a B cell response, Tevogen Bio's design aims to leverage the Company's proprietary Tevogen.AI-powered PredicTcell technology to identify peptides which stimulate a T cell response.
benzinga.com
On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. TVGN, a clinical-stage immunotherapy company.
See all news
